/stocks — the workspaceLOADING
All RGNXSEC filings, by type → · Earnings date & implied move · Search inside filings
REGENXBIO Inc. (RGNX) is a biological products, (no diagnostic substances) company. Piotroski F-Score 3/7. 14 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-05 from RGNX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind RGNX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from RGNX’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on RGNX plus an auto-SWOT — built from RGNX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate RGNX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has RGNX been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
The fair-value line is RGNX’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from RGNX’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
No tracked institution reported a position in RGNX in the latest 13F round.
Total return including reinvested dividends, from RGNX’s adjusted closing prices. Past return is not a forecast and not investment advice.
The estimators disagree by 131% of the midpoint. A wide band is itself the finding: this company’s value depends heavily on which yardstick you use, so treat any single number for RGNX— ours or anyone else’s — with corresponding caution.
The band is the interquartile range of every estimator that could run on RGNX’s filings: the median P/E, P/S, P/B and P/FCF this stock has actually traded at over 11years of history applied to today’s fundamentals, a two-stage discounted-cash-flow estimate. With four or more estimators we take the interquartile range, so a single wild reading cannot define the band; with two or three we show the full spread, because trimming the tails off three points does not remove noise, it manufactures confidence. We publish a range rather than one number because the estimators genuinely disagree, and averaging that disagreement away would hide the most useful part.
Valuation labels describe only where the price sits against that band:
These labels are positional, not predictive. Premium means the current share price sits above the band computed from RGNX’s own filings and trading history. It does not mean the stock cannot keep rising, that a fall is expected, or that the market has it wrong. Equally, Discount means the price sits below that band — it does not imply the stock is cheap in any meaningful sense, that it is worth buying, or that the market has mispriced it. A company can trade above or below its own historical range for years, and often does, for reasons the range knows nothing about.
The labels describe where today’s price falls against a calculated band. Nothing more than that.
Measured disagreement is our answer to a locked “uncertainty rating”: it is simply how far the estimators spread as a share of the midpoint, tiered Low / Moderate / High / Extreme, with the raw spread shown beside it. A wide band earns a high tier because the answer then depends heavily on which yardstick you pick — that is a finding, not a defect.
Filing health is computed separately and never looks at price. It reads the Piotroski F-Score, the Altman Z-Score and the Beneish M-Score straight from the filings: means none of them flagged, means one moderate flag, means a distress or manipulation flag, or several softer ones. For banks and insurers it reads : all three scores were built on non-financial companies and their authors excluded financials, so for a balance-sheet business they measure the shape of the business rather than its health. Keeping the two axes apart is deliberate — a cheap company with weak filings is a very different object from a cheap company with sound ones, and a single blended verdict would hide which you are looking at.
This is a computed description of a security against a published formula — not investment advice, not a recommendation, and not a price target. Labels describe RGNX against the band above; they say nothing about whether it suits your circumstances. Historical multiples are not a forecast, and a company can stay outside its own historical range for years. Educational information only.
Why some estimators are skipped. A multiple can be arithmetically computable and still meaningless. GAAP depreciation crushes REIT earnings, so we do not price a REIT off P/E; revenue and free cash flow are not comparable measures for a bank or an insurer, so those are dropped too. We would rather show you the estimators we trust and name every one we withheld, with the reason, than quietly fold in a number we do not believe.
Every number above is arithmetic you can redo. The inputs are RGNX’s own SEC filings and our price history; the formulas are stated on this page. There is no proprietary black box, and there is nothing here you have to take on trust.
No lawmaker has disclosed a trade in RGNX under the STOCK Act.
Projected from RGNX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentRGNX files or announces.
RGNX's earnings reaction has been evenly split — 4 up, 4 down across its last 8 reports.
Each figure is one earnings reaction — how much RGNX moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
The average is inflated by its most volatile prints (+25.4% and -43.0%).
A more typical earnings reaction has been approximately ±5.0%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-06 | +2.1% |
| 2026-05-14 | -43.0% |
| 2026-03-05 | -5.4% |
| 2025-11-06 | -3.4% |
| 2025-08-07 | -4.6% |
| 2025-05-12 | +8.8% |
| 2025-03-13 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +0.7% |
| 2024-11-06 | +25.4% |
| PAKOLA STEVEChief Medical Officer | SELL | $29K | view → |
| PAKOLA STEVEChief Medical Officer | SELL | $689K | view → |
| PAKOLA STEVEChief Medical Officer | SELL | $169K | view → |
| PAKOLA STEVEChief Medical Officer | SELL | $53K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.